CancerNetwork Members: Login | Register
Become a fan on  Facebook  Add us on  Google Plus Follow us on  Twitter Join us on LinkedIn Sign up for our Newsletters Subscribe to our RSS Feed

 

CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
NURSES
PATIENTS
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

Home » Bladder Cancer

ONCOLOGY. Vol. 23 No. 2
Pages: 1  2  
Next
SECOND OPINION 

A Man With Changes in the Urinary Bladder: Benign Metaplasia or Adenocarcinoma?

By Thomas W. Flaig, MD1, Francisco G. La Rosa, MD2, Kristen McKinney, MD3, Paul Maroni, MD4, Shandra Wilson, MD4 | February 18, 2009
1Assistant Professor, Department of Medicine, Division of Medical Oncology 2Assistant Professor, Department of Pathology 3Assistant Professor, Department of Radiology 4Assistant Professor, Department of Surgery, Division of Urology, University of Colorado, School of Medicine, Aurora, Colorado

SECOND OPINION
Multidisciplinary Consultations on Challenging Cases

The University of Colorado Denver School of Medicine faculty holds weekly second opinion conferences focusing on cancer cases that represent most major cancer sites. Patients seen for second opinions are evaluated by an oncologic specialist. Their history, pathology, and radiographs are reviewed during the multidisciplinary conference, and then specific recommendations are made. These cases are usually challenging, and these conferences provide an outstanding educational opportunity for staff, fellows, and residents in training.

The second opinion conferences include actual cases from genitourinary, lung, melanoma, breast, neurosurgery, gastrointestinal, and medical oncology. On an occasional basis, ONCOLOGY will publish the more interesting case discussions and the resultant recommendations. We would appreciate your feedback; please contact us at second.opinion@uchsc.edu.

E. David Crawford, MD
Al Barqawi, MD
Guest Editors

University of Colorado Health Sciences Center
and Univeristy of Colorado Cancer Center
Denver, Colorado

The patient is a 39-year-old man who presents with pelvic lymphadenopathy. He has a history of ureteral reflux disease, recurrent nephrolithiasis, right nephrectomy, ileal loop diversion of the left ureter, and radical cystectomy for “bladder cancer,” which he underwent 3 years ago. The lymphadenopathy was discovered incidentally during recent imaging.

Case Report

History

Dr. Thomas Flaig: This patient has a complex medical and surgical history that is remarkable for several urologic problems and procedures. As a young child, he had severe ureteral reflux disease, and 30 years ago, he underwent a right nephrectomy to remove a nonfunctioning kidney that was damaged by the reflux. At the same time, he had an ileal loop diversion on the left side, presumably to prevent similar damage to the left kidney. The patient also has a history of recurrent nephrolithiasis requiring extracorporeal shock-wave lithotripsy on multiple occasions.

Three years ago, as part of a workup for hematuria, cystoscopic evaluation revealed a bladder mass. The patient reports that he was diagnosed with “bladder cancer” and had a radical cystectomy. He is now seen in our center for evaluation of nephrolithiasis and was found to have lymphadenopathy in the pelvis.

His past medical history is notable for multiple sclerosis. A review of his family history is significant for multiple sclerosis in his mother, but no history of cancer in any first-degree relatives. His social history reveals ongoing tobacco use.

Physical Exam

Dr. Flaig: On physical exam, the patient’s temperature is 96.6°F, pulse rate is 66/min, respiratory rate is 16/min, and his blood pressure is 132/72 mm Hg. He is in no acute distress. His lungs are clear to auscultation bilaterally. The cardiac exam reveals a regular rhythm without murmur. His abdomen is soft and nontender. Surgical scars are present and consistent with previous operative procedures. An ostomy site is present on the left side of the abdomen. His extremities are without any sign of infection or gross inflammation.

Laboratory Findings

Dr. Flaig: Laboratory findings include the following: sodium, 140 mMol/L; creatinine, 1.0 mg/dL; ALT, 26 U/L; total bilirubin, 0.5 mg/dL; albumin, 4.2 g/dL; white blood cell count, 10.9 × 109/L; hemoglobin, 16.3 g/dL; and platelets, 266 × 109/L.

Discussion

Pathology

Dr. Flaig: Dr. La Rosa, would you please review the patient’s pathologic findings?

FIGURE 1
Specimen #1—Histologic examination of a 3-year-old cystectomy specimen showed extensive proliferation of glands in the lamina propria (H&E, 4x objective).
FIGURE 2
Specimen #2—Cystectomy specimen showing submucosal glands lined by columnar epithelium, including goblet cells and Paneth cells (intestinal metaplasia) (H&E, 20x objective).

Dr. Francisco La Rosa: We reviewed for second opinion diagnosis the outside surgical pathology case established for this patient, consisting of a urinary bladder biopsy and a cystectomy specimen from 3 years ago. Histologic examination of the cystectomy specimen showed extensive proliferation of glands in the lamina propria (Figure 1), which were lined by columnar epithelium, including goblet cells and Paneth cells ­(Figure 2). Some sections showed pools of mucinous material with extravasation into the stroma (Figure 3).

FIGURE 3
Specimen #3—Cystectomy specimen showing pools of submucosal mucinous material with extravasation into the stroma (H&E 20x objective).

Even though the diagnosis in the outside pathology report for the biopsy specimen was of an “adenocarcinoma,” we found no evidence of significant nuclear atypia, mitotic activity, necrosis, or signet ring cells. In addition, no evidence of stromal reaction or significant chronic inflammation was present around the glands and the mucinous pools. The muscularis propria had no evidence of invasion. Also submitted for our review were three right iliac lymph nodes taken at the time of the cystectomy, which showed no evidence of malignancy.

Tumors of the urinary bladder are mostly (> 90%) derived from the urothelium (transitional cell mucosa) and are usually composed of papillary formations with different grades of malignant differentiation and potential for invasion.[1] Some of these tumors may present with areas of squamous and/or glandular differentiation. In contrast, cystitis cystica and cystitis glandularis are rare benign metaplastic changes of the urinary bladder characterized by an increased growth of the normal glandular elements within the bladder mucosa (Brunn glands). These are primarily reactive changes usually associated with chronic inflammatory processes, and should not be considered premalignant lesions. The histologic features are nests of von Brunn glands with cystic changes, which define cystitis cystica, and mucin-filled goblet cell metaplasia, which defines cystitis glandularis. In our discussion case, we observed these changes, both in the biopsy and in the cystectomy specimens.

Cystitis glandularis is found mostly in the trigone. The cystic dilatation of the glands is followed by progressive flattening of the glandular epithelium, giving origin to the morphologic changes known as cystitis cystica. Cystitis glandularis may be seen with microscopic changes in small aggregates of mucosal glands, but it may also occur as grossly identifiable poly­poid masses suggesting a neoplastic process.

The histopathologic findings of cystitis glandularis and cystica should not present a diagnostic problem. The issue arises when we need to differentiate between these benign lesions and adenocarcinoma.[2,3] Cystitis glandularis and cystica are characterized by only minimal nuclear atypia without the observation of any stromal reaction, as is seen in invasive adenocarcinoma. The glands in cystitis glandularis and cystica show a well defined outline, whereas the glands in cases of adenocarcinoma are irregular and show an infiltrative behavior. Thus, invasiveness, irregular glandular contours, desmoplastic stromal reaction, and nuclear atypia are the main features that define an adenocarcinoma. Extravasation of mucinous material into the stroma may be seen in the intestinal type of cystitis glandularis—as an isolated finding, it may be difficult to differentiate from a malignant process.[4,5]

Pages: 1  2  
Next
 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.






 
RELATED CONTENT

Bladder Cancer Recurrence High, Better Follow-Up Care Needed
June 17, 2013
Cannabis Linked to Decreased Bladder Cancer Risk
May 28, 2013
Advanced Urothelial Carcinoma: Moving the Field Forward
ONCOLOGY,  March 12, 2013
Targeted Therapy in Advanced Urothelial Carcinoma
ONCOLOGY,  March 12, 2013
ASCO GU: Clinical Staging in Bladder Cancer Inaccurate Nearly Half of the Time
February 19, 2013
 
TOPIC INDEX

Cancer Types

 
  • Breast
  • Breast (HER2+)
  • Breast (Triple-Negative)
  • CML
  • Colorectal
  • Gastrointestinal
  • GIST
  • Genitourinary
  • Gynecologic
  • Head & Neck
  • Hematology
  • Kidney (Renal Cell)
  • Leukemia
  • Lung
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Ovarian
  • Prostate
  • Sarcoma

Supportive Care

More Topics

  • Bone Metastases
  • End-of-Life Care
  • Palliative Care
  • Ethics in Oncology
  • Practice Management
  • Practice & Policy


All Topics 


 
   SEARCH MEDICA RX
   Browse drugs by name:
A B C D E F G H I J
K L M N O P Q R S T
U V W X Y Z All      
   Search for drugs:
Search

 

 
FROM PHYSICIANS PRACTICE
Key Differences between FQHCs and RHCs
Chastity Werner, RHIT, June 13, 2013
FQHCs and RHCs take up a unique niche among physician practices. And that affects compensation and billing.
Improving Care Coordination in Your Practice
Susanne Madden,  June 12, 2013
Practices are feverishly working to control the rising costs of healthcare - effective care coordination can help.
Refunding Overpayments: Two Options for Medical Practices
Ericka L. Adler,  June 12, 2013
Medicare and Medicaid providers must return overpayments once identified. Here are two different refund approaches for practices to consider when necessary.
Four Easy Ways to Boost Patient Time of Service Collections
Aubrey Westgate,  June 12, 2013
Simple ways your medical practice staff can increase the likelihood patients will pay when presenting for appointments.
iPad Alternatives for Mobile Physicians
Marisa Torrieri, June 11, 2013
As more physicians are seeing the merits of media tablets, the market is expanding, too.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Papillary Thyroid Carcinoma
  • Robotic-Assisted Radical Prostatectomy: Who Is Benefiting?
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • ASCO: Long-Term Tamoxifen Benefit for Breast Cancer Confirmed
  • A 48-Year-Old Woman With Irregular Vaginal Bleeding
  • Cannabis Linked to Decreased Bladder Cancer Risk
  • Breast Cancer Screening, Risk, and Options for High-Risk Women
  • Recurrent Epithelial Ovarian Cancer: An Update on Treatment
  • Rising PSA Level in a 46-Year-Old Man
  • ASCO: Long-Term Tamoxifen Benefit for Breast Cancer Confirmed
  • ASCO: Dabrafenib Shows Activity in BRAF-Mutated NSCLC Patients
  • Preventing Burnout in Oncology
  • ASCO: Yoga Reduces Insomnia in Breast Cancer Patients Treated With Hormone Therapy
  • Physical Activity Across the Cancer Continuum
  • Exercise After Cancer Diagnosis: Time to Get Moving
Click here to subscribe to our newsletter
 
COMMENTS
  • Most Commented
  • Most Recent
  • 50 Shades of Pink—And Why It Helps to Know the Difference
  • Preventing Exposure to Hazardous Drugs
  • ASCO: Vinegar Screening Significantly Reduces Cervical Cancer Mortality
  • ASCO: Sulforaphane in Prostate Cancer Found Worthy of Further Investigation
  • Study: Recurrent Heartburn Ups Risk for Throat Cancer
  • HER2-Directed Therapy for Metastatic Breast Cancer
  • Accelerated Partial-Breast Irradiation: The Current State of Our Knowledge
  • It’s Time for Clinicians to Reconsider Their Proscription Against the Use of Soyfoods by Breast Cancer Patients
  • 50 Shades of Pink—And Why It Helps to Know the Difference
  • ASCO: No Benefit From Avastin in Newly Diagnosed Glioblastoma
Click here to subscribe to our newsletter


CancerNetwork on Facebook
 
SearchMedica Search Result

Find peer-reviewed literature and websites for practicing medical professionals

CME on Bladder Cancer
Evidence on Bladder Cancer
Guidelines on Bladder Cancer
Patient Education on Bladder Cancer
Clinical Trials on Bladder Cancer
Practical Articles on Bladder Cancer
Research and Reviews on Bladder Cancer
All "Bladder Cancer" results


CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy